Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription
Posted May 28, 2007
Length still more important
Analysis of: Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA | www.therapeuticsdaily.com
Author: GLG Member Program Contributor
Though a once-a-day amoxicillin is likely to lead to more compliance, giving a drug for a shorter period of time would be better. It will allow for a full course of therapy. The longer a drug needs to be taken the less likely it will be completed as patients will tend to stop therapy once they feel...
Posted May 24, 2007
Amoxicillin PULSYS approval
Analysis of: Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA | www.therapeuticsdaily.com
Author: GLG Member Program Contributor
The main advantage of this formulation is being once a day, to improve compliance. The standard dose seems to be 775 mg/d for 7 days (compared to 500 tid for 10-days) which also could potentially decrease side effects with a lower dose and shorter duration.
Posted May 23, 2007
Compare it to Lotrel
Analysis of: Amlodipine And Olmesartan Study Results Released; Late Breaker Presented At American Society Of Hypertension Twenty-Second Annual Scientific Meeting | www.medicalnewstoday.com
Author: GLG Member Program Contributor
We already have combination meds that include a CALCIUM CHANNEL BLOCKER and an ACE. Amlodipine is in one of these combination products. Combination therapy is the way to do to get patients to goal with a lower pill burden. Which combo of an ACE or an ARB  with Amlodipine will be better...
Posted May 21, 2007
Lower prices in the future for non-sedating anti-histamines
Analysis of: Ranbaxy Receives Tentative FDA Approval For Fexofenadine Hydrochloride Tablets | www.medicalnewstoday.com
Author: GLG Member Program Contributor
This is the second generic version of Fenofexadine(Allegra).  Its presence on the market should result in lower prices for this generic drug. It puts even greater pressure on Zyrtec and Clarinex to maintain market share.
Posted May 21, 2007
Generic Fexofenadine
Analysis of: Ranbaxy Receives Tentative FDA Approval For Fexofenadine Hydrochloride Tablets | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Fexofenadine, a popular oral anti-histamine, is an attractive target, but the market for oral anti-histamines is very competitive. 
Posted May 18, 2007
New stress agent at hand
Analysis of: CV Therapeutics Submits New Drug Application For Regadenoson | www.pipelinereview.com
Author: GLG Member Program Contributor
An NDA for Regadenoson has been submitted this week. The compound has a few significant benefits over adenosine: 1- bolus vs. 4 minute drip 2- Fewer symptoms. The compound has been shown to lead to essentially identical stress images. The drug will be marketed by Astellas who will push hard to switch...
Posted May 15, 2007
First Proof of the Use of Novel Magnetic Remote Controlled System for VT management
Analysis of: Initial Experience with a Novel Remote-Guided Magnetic Catheter Navigation System for Left Ventricular Scar Mapping and Ablation in a Porcine Model of Healed Myocardial Infarction | www.blackwell-synergy.com
Author: GLG Member Program Contributor
There are millions of VT patient all over the world. Quite a few of them have Defibrillators implanted. However because VT ablation is a complex procedure very few cases are attempted worldwide in comparison to the number of cases present. Newer technologies might change the scenario. Use of remote...
Posted May 14, 2007
Yes, but will not curb TB in the 3rd World
Analysis of: Screening 'may help stem TB rise' | news.bbc.co.uk
Author: GLG Member Program Contributor
All individuals from 3rd world nations should be screened for communicable diseases upon entry to a developed nation. This may stem the tide of spread in that country. It does not affect the real issue of controlling disease where it originates.
Posted May 14, 2007
Where there is HOPE-
Analysis of: King Pharmaceuticals Announces Plan to Present Results From Phase III Clinical Trial Evaluating Altace® As Monotherapy And In Combination With Hydrochlorothiazide At The American Society Of Hypertension Annual Meeting | www.kingpharm.com
Author: GLG Member Program Contributor
Only good can come from this. Combination products are now the way to go in control of hypertension. The HOPE study has shown that Altace has evidence based positive outcomes. King Pharma can only benefit from this.
Posted May 9, 2007
Early diagnosis of TB
Analysis of: Screening 'may help stem TB rise' | news.bbc.co.uk
Author: GLG Member Program Contributor
Not surprising - maybe UK's NHS should have asked "developing countries" before conducting the study.
Previous Page : 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Next271 to 280 of 419

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353